Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs AUROBINDO PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON AUROBINDO PHARMA BIOCON /
AUROBINDO PHARMA
 
P/E (TTM) x 34.9 17.8 195.6% View Chart
P/BV x 4.4 3.9 114.5% View Chart
Dividend Yield % 0.2 0.3 81.6%  

Financials

 BIOCON    AUROBINDO PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-19
AUROBINDO PHARMA
Mar-19
BIOCON /
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs707830 85.2%   
Low Rs554527 105.1%   
Sales per share (Unadj.) Rs91.9333.9 27.5%  
Earnings per share (Unadj.) Rs16.740.4 41.4%  
Cash flow per share (Unadj.) Rs24.251.8 46.7%  
Dividends per share (Unadj.) Rs1.002.50 40.0%  
Dividend yield (eoy) %0.20.4 43.0%  
Book value per share (Unadj.) Rs101.6237.1 42.9%  
Shares outstanding (eoy) m600.00585.91 102.4%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.92.0 337.6%   
Avg P/E ratio x37.716.8 224.4%  
P/CF ratio (eoy) x26.113.1 199.0%  
Price / Book Value ratio x6.22.9 216.8%  
Dividend payout %6.06.2 96.6%   
Avg Mkt Cap Rs m378,330397,569 95.2%   
No. of employees `0006.117.9 34.3%   
Total wages/salary Rs m11,65325,849 45.1%   
Avg. sales/employee Rs Th8,994.310,956.9 82.1%   
Avg. wages/employee Rs Th1,900.71,447.7 131.3%   
Avg. net profit/employee Rs Th1,635.31,324.3 123.5%   
INCOME DATA
Net Sales Rs m55,144195,636 28.2%  
Other income Rs m1,4441,553 93.0%   
Total revenues Rs m56,588197,189 28.7%   
Gross profit Rs m15,88339,519 40.2%  
Depreciation Rs m4,4786,680 67.0%   
Interest Rs m7092,626 27.0%   
Profit before tax Rs m12,14031,767 38.2%   
Minority Interest Rs m927 33.3%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m2,1237,269 29.2%   
Profit after tax Rs m10,02623,645 42.4%  
Gross profit margin %28.820.2 142.6%  
Effective tax rate %17.522.9 76.4%   
Net profit margin %18.212.1 150.4%  
BALANCE SHEET DATA
Current assets Rs m48,228153,645 31.4%   
Current liabilities Rs m30,376120,429 25.2%   
Net working cap to sales %32.417.0 190.7%  
Current ratio x1.61.3 124.4%  
Inventory Days Days68135 50.5%  
Debtors Days Days8664 134.2%  
Net fixed assets Rs m64,130103,909 61.7%   
Share capital Rs m3,000586 512.0%   
"Free" reserves Rs m57,980138,322 41.9%   
Net worth Rs m60,980138,908 43.9%   
Long term debt Rs m15,7661,800 876.1%   
Total assets Rs m121,924264,544 46.1%  
Interest coverage x18.113.1 138.4%   
Debt to equity ratio x0.30 1,995.8%  
Sales to assets ratio x0.50.7 61.2%   
Return on assets %8.89.9 88.7%  
Return on equity %16.417.0 96.6%  
Return on capital %16.823.8 70.3%  
Exports to sales %28.149.6 56.7%   
Imports to sales %18.918.8 100.4%   
Exports (fob) Rs m15,50697,091 16.0%   
Imports (cif) Rs m10,39936,741 28.3%   
Fx inflow Rs m15,50697,316 15.9%   
Fx outflow Rs m10,39940,589 25.6%   
Net fx Rs m5,10756,727 9.0%   
CASH FLOW
From Operations Rs m11,54616,220 71.2%  
From Investments Rs m-7,138-28,768 24.8%  
From Financial Activity Rs m-2,41719,191 -12.6%  
Net Cashflow Rs m2,1036,656 31.6%  

Share Holding

Indian Promoters % 40.4 54.1 74.7%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 8.0 105.7%  
FIIs % 10.7 27.7 38.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 10.2 195.1%  
Shareholders   109,995 69,601 158.0%  
Pledged promoter(s) holding % 0.0 8.6 0.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   STRIDES PHARMA SCIENCE  ELDER PHARMA  SUVEN LIFE SCIENCES  ALEMBIC PHARMA  WOCKHARDT  

Compare BIOCON With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 470 Points Lower; Tata Motors & Tata Steel Fall 6%(Closing)

Indian share markets witnessed huge selling pressure today, in line with global equities and fell on to bearish territory.

Related Views on News

BIOCON Announces Quarterly Results (2QFY21); Net Profit Down 23.9% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, BIOCON has posted a net profit of Rs 2 bn (down 23.9% YoY). Sales on the other hand came in at Rs 17 bn (up 11.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jan 18, 2021 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS